Home/Filings/4/0000899243-20-017611
4//SEC Filing

Kelly Patrick F. 4

Accession 0000899243-20-017611

CIK 0001538927other

Filed

Jun 23, 8:00 PM ET

Accepted

Jun 24, 9:25 PM ET

Size

10.0 KB

Accession

0000899243-20-017611

Insider Transaction Report

Form 4
Period: 2020-06-23
Kelly Patrick F.
SVP, Chief Medical Officer
Transactions
  • Purchase

    Common Stock

    2020-06-23+42,95942,959 total
  • Sale

    Enterprise 4 Junior Stock

    2020-06-235,8440 total
  • Sale

    Enterprise 3 Junior Stock

    2020-06-2317,5330 total
  • Sale

    Enterprise 6 Junior Stock

    2020-06-2340,9110 total
Footnotes (1)
  • [F1]Effective immediately upon the closing of the Registrant's initial public offering on June 23, 2020, the reporting person converted (i) 17,533 shares of Enterprise 3 Junior Stock at a conversion rate of 0.7822 shares of common stock per one share of Enterprise 3 Junior Stock, (ii) 5,844 shares of Enterprise 4 Junior Stock at a conversion rate of 0.7585 shares of common stock per one share of Enterprise 4 Junior Stock and (iii) 40,911 shares of Enterprise 6 Junior Stock at a conversion rate of 0.6065 shares of common stock per one share of Enterprise 6 Junior Stock, resulting in his acquisition of 42,959 shares of common stock.

Issuer

Forma Therapeutics Holdings, Inc.,

CIK 0001538927

Entity typeother

Related Parties

1
  • filerCIK 0001814771

Filing Metadata

Form type
4
Filed
Jun 23, 8:00 PM ET
Accepted
Jun 24, 9:25 PM ET
Size
10.0 KB